vTv Therapeutics (VTVT) Assets Average (2015 - 2026)

vTv Therapeutics has disclosed Assets Average across 12 years of filings, most recently posting $94.4 million for Q1 2026.

• Assets Average for Q1 2026 came in at $94.4 million, up 168.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $94.4 million (up 168.46% YoY), and the FY2025 annual result was $64.1 million, up 160.05% from the prior year.
• Assets Average came in at $94.4 million for Q1 2026 at vTv Therapeutics, roughly flat from $94.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $94.7 million in Q4 2025 to a low of $13.0 million in Q4 2023.
• The 5-year median for Assets Average is $34.4 million (2022), against an average of $40.9 million.
• Across the five-year window, Assets Average sank 62.27% in 2023 and jumped 213.89% in 2024, its largest moves.
• vTv Therapeutics' Assets Average stood at $34.4 million in 2022, then tumbled by 62.27% to $13.0 million in 2023, then surged by 213.89% to $40.7 million in 2024, then jumped by 132.58% to $94.7 million in 2025, then retreated by 0.36% to $94.4 million in 2026.
• The last three Assets Average figures came in at $94.4 million (Q1 2026), $94.7 million (Q4 2025), and $63.0 million (Q3 2025), per Business Quant data.